Skip to main content
Top
Published in: BMC Gastroenterology 1/2008

Open Access 01-12-2008 | Study protocol

Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study

Authors: Llorenç Caballería, Ma Antonia Auladell, Pere Torán, Guillem Pera, Dolores Miranda, Alba Alumà, José Dario Casas, Laura Muñoz, Carmen Sanchez, Albert Tibau, Marti Birules, Santiago Canut, Jesús Bernad, Josep Aubà, Miren Maite Aizpurua, Enriqueta Alcaraz

Published in: BMC Gastroenterology | Issue 1/2008

Login to get access

Abstract

Background

Non alcoholic fatty liver disease (NAFL) consists in the accumulation of fat vacuoles in the cytoplasm of hepatocytes. Many etiologic factors are associated with NAFL, such as, the metabolic syndrome factors, medications, bariatric surgery, nutritional disorders. However, very little information is available on the clinical relevance of this disorder as a health problem in the general population.

Methods and design

The aim of the study is establish the risk factors most frequently associated with NAFL in a general adult population assigned to the primary care units and to investigate the relationship between each component of the metabolic syndrome and the risk of having a NAFL.
A population based case-control, observational and multicenter study will be carried out in 18 primary care units from the "Area de Gestión del Barcelonés Nord y Maresme" (Barcelona) attending a population of 360,000 inhabitants and will include 326 cases and 370 controls. Cases are defined as all subjects fulfilling the inclusion criteria and with evidence of fatty liver in an abdominal ultrasonography performed for any reason. One control will be randomly selected for each case from the population, matched for age, gender and primary care center. Controls with fatty liver or other liver diseases will be excluded.
All cases and controls will be asked about previous hepatic diseases, consumption of alcohol, smoking and drugs, and a physical examination, biochemical analyses including liver function tests, the different components of the metabolic syndrome and the HAIR score will also be performed. Paired controls will also undergo an abdominal ultrasonography.

Discussion

This study will attempt to determine the factors most frequently associated with the presence of NAFL investigate the relationship between the metabolic syndrome and the risk of fatty liver and study the influence of the different primary care professionals in avoiding the evolution of the disease.
Literature
1.
go back to reference Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proc. 1980, 55 (7): 434-438. Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proc. 1980, 55 (7): 434-438.
2.
go back to reference Bedogni G, Bellentani S: Fatty liver: How frequent is it and why?. Ann Hepatol. 2004, 3: 63-65.PubMed Bedogni G, Bellentani S: Fatty liver: How frequent is it and why?. Ann Hepatol. 2004, 3: 63-65.PubMed
3.
go back to reference Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346: 1221-1331. 10.1056/NEJMra011775.CrossRefPubMed Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346: 1221-1331. 10.1056/NEJMra011775.CrossRefPubMed
4.
go back to reference Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001, 21: 27-41. 10.1055/s-2001-12927.CrossRefPubMed Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001, 21: 27-41. 10.1055/s-2001-12927.CrossRefPubMed
5.
go back to reference Yourssef W, McCullough AJ: Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis. 2002, 13: 17-30. Yourssef W, McCullough AJ: Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis. 2002, 13: 17-30.
6.
go back to reference Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002, 287: 356-359. 10.1001/jama.287.3.356.CrossRefPubMed Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002, 287: 356-359. 10.1001/jama.287.3.356.CrossRefPubMed
8.
go back to reference Pagano C, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M: Non-alcoholic steatohepatitis, insulin resistance and metabolic syndrome. Further evidence for an etiologic association. Hepatology. 2002, 35: 367-72. 10.1053/jhep.2002.30690.CrossRefPubMed Pagano C, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M: Non-alcoholic steatohepatitis, insulin resistance and metabolic syndrome. Further evidence for an etiologic association. Hepatology. 2002, 35: 367-72. 10.1053/jhep.2002.30690.CrossRefPubMed
9.
go back to reference Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003, 98: 960-7. 10.1111/j.1572-0241.2003.07486.x.CrossRefPubMed Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003, 98: 960-7. 10.1111/j.1572-0241.2003.07486.x.CrossRefPubMed
10.
go back to reference Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study. Hepatology. 2005, 42: 44-52. 10.1002/hep.20734.CrossRefPubMed Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study. Hepatology. 2005, 42: 44-52. 10.1002/hep.20734.CrossRefPubMed
11.
go back to reference Caballería Ll, Auladell AM, Torán P, Miranda D, Aznar J, Pera G, Gil D, Muñoz L, Planas J, Canut S, Bernad J, Aubà J, Pizarro G, Aizpurua MM, Altaba A, Tibau A: Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. BMC Gastroenterology. 2007, 7: 41-10.1186/1471-230X-7-41.CrossRefPubMedPubMedCentral Caballería Ll, Auladell AM, Torán P, Miranda D, Aznar J, Pera G, Gil D, Muñoz L, Planas J, Canut S, Bernad J, Aubà J, Pizarro G, Aizpurua MM, Altaba A, Tibau A: Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. BMC Gastroenterology. 2007, 7: 41-10.1186/1471-230X-7-41.CrossRefPubMedPubMedCentral
12.
go back to reference Dixon JB, Bhatal PS, O'Brien PE: Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severity obese. Gastroenterology. 2001, 121: 91-100. 10.1053/gast.2001.25540.CrossRefPubMed Dixon JB, Bhatal PS, O'Brien PE: Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severity obese. Gastroenterology. 2001, 121: 91-100. 10.1053/gast.2001.25540.CrossRefPubMed
13.
go back to reference Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP: The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007, 45: 846-854. 10.1002/hep.21496.CrossRefPubMed Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP: The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007, 45: 846-854. 10.1002/hep.21496.CrossRefPubMed
14.
go back to reference NHO: Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. 1999, Geneva: Department of Noncomunicable disease Surveillance, Word Health Organization NHO: Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. 1999, Geneva: Department of Noncomunicable disease Surveillance, Word Health Organization
15.
go back to reference Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E, EGIR-RISC Study Group: EGIR-RISC Study Group. The EGIR-RISC Study (the European Group for the study of Insulin Resistence: Relationship between insulin sensitivity and cardiovascular disease risc): I. Methodology and objectives. Diabetologia. 2004, 47: 566-570. 10.1007/s00125-004-1335-5.CrossRefPubMed Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M, Ferrannini E, EGIR-RISC Study Group: EGIR-RISC Study Group. The EGIR-RISC Study (the European Group for the study of Insulin Resistence: Relationship between insulin sensitivity and cardiovascular disease risc): I. Methodology and objectives. Diabetologia. 2004, 47: 566-570. 10.1007/s00125-004-1335-5.CrossRefPubMed
16.
go back to reference Executive summary of the third report of the National Cholesterol Education (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adults Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.CrossRef Executive summary of the third report of the National Cholesterol Education (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adults Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.CrossRef
17.
go back to reference Alberti KG, Zimmet P, Shaw J: Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006, 23: 469-80. 10.1111/j.1464-5491.2006.01858.x.CrossRefPubMed Alberti KG, Zimmet P, Shaw J: Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006, 23: 469-80. 10.1111/j.1464-5491.2006.01858.x.CrossRefPubMed
18.
go back to reference Caballería J, Rodés J: Esteatohepatitis no alcohólica. Med Clin (Barc). 2003, 120: 670-675. 10.1157/13047319.CrossRef Caballería J, Rodés J: Esteatohepatitis no alcohólica. Med Clin (Barc). 2003, 120: 670-675. 10.1157/13047319.CrossRef
19.
go back to reference Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002, 123: 1705-1725. 10.1053/gast.2002.36572.CrossRefPubMed Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002, 123: 1705-1725. 10.1053/gast.2002.36572.CrossRefPubMed
Metadata
Title
Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study
Authors
Llorenç Caballería
Ma Antonia Auladell
Pere Torán
Guillem Pera
Dolores Miranda
Alba Alumà
José Dario Casas
Laura Muñoz
Carmen Sanchez
Albert Tibau
Marti Birules
Santiago Canut
Jesús Bernad
Josep Aubà
Miren Maite Aizpurua
Enriqueta Alcaraz
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2008
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-8-44

Other articles of this Issue 1/2008

BMC Gastroenterology 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine